AI assistant
bioAffinity Technologies, Inc. — Director's Dealing 2022
Nov 22, 2022
35439_dirs_2022-11-22_01d88829-1ad6-4fc3-8813-3251915a9745.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2022-11-17
Reporting Person: Rebel Vivienne I (EVP, Chief Sci. & Med. Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-11-17 | Common Stock, par value $0.007 | A | 7239 | — | Acquired | 14381 | Direct |
Footnotes
F1: Represents a grant from bioAffinity Technologies, Inc. (the "Issuer") to Dr. Rebel of 7,239 restricted shares of the Issuer's common stock, par value $0.007 (the "Common Stock"), on November 17, 2022 under the Issuer's 2014 Equity Incentive Plan. The restricted stock will begin vesting on December 17, 2022 in 12 monthly installments, the first 11 of which will be of 603 shares of Common Stock and the last of which will be of the remaining 606 shares of Common Stock, subject to Dr. Rebel's continuous service to the Issuer through each vesting date.